In Competition Law and Policy Debate, Raphaël De Coninck highlights the European Commission’s recent interest in assessing the impact of pharmaceutical mergers on innovation. The article discusses the Commission’s approach and argues in favor of developing a consistent framework for assessing the impact of mergers on innovations. To read more, click the link below.
How Views On US Healthcare Price Transparency Are Changing
Previously in a series of policy letters, Federal Trade Commission staff expressed concerns that transparency could lead to coordinated behavior and higher...